The Emirates Drug Authority has announced the approval of a new treatment, Rinvoq (upadacitinib), for the management of non-segmental vitiligo in adults and adolescents aged 12 and over. This marks a significant milestone as it becomes the first oral medication licensed for this particular group of patients requiring systemic treatment via blood-borne medications.
The medication is administered once daily by mouth, providing an additional treatment option for eligible patients under established medical guidelines.
Pioneering Pharmacological Innovations
Notably, the UAE has become the first country in the world to expand the use of Rinvoq, showcasing its advanced standing in adopting the latest pharmaceutical innovations and expediting their availability.
Commitment to Regulatory Excellence
The Emirates Drug Authority emphasised that this approval is part of a sophisticated regulatory framework that responds to global scientific developments, thereby contributing to advancements in the pharmaceutical sector and enhancing therapeutic outcomes for patients.
Encouraging Early Diagnosis
The authority also urged members of the community to consult a specialist upon noticing any unusual skin colour changes. Early diagnosis and assessment are crucial for determining the most appropriate treatment for each patient.